Fourth-generation epidermal growth factor receptor-tyrosine kinases inhibitors: hope and challenges. | Transl Cancer Res;13(8): 3929-3934, 2024 Aug 31. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Fourth-generation epidermal growth factor receptor-tyrosine kinases inhibitors: hope and challenges.

Su, Chunxia; Sun, Shi-Yong.

Affiliation

Su C; Department of Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
Sun SY; Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA.

Transl Cancer Res ; 13(8): 3929-3934, 2024 Aug 31.

Article in En | MEDLINE | ID: mdl-39262457

Key words

EGFR-tyrosine kinase inhibitors (EGFR-TKIs); Epidermal growth factor receptor (EGFR); fourth-generation; lung cancer; osimertinib

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Transl Cancer Res Year: 2024 Document type: Article Affiliation country: China Country of publication: China

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Transl Cancer Res Year: 2024 Document type: Article Affiliation country: China Country of publication: China